Skip to content

Neonatal Seizure Registry - Developmental Functional EValuation

Neonatal Seizure Registry - Developmental Functional EValuation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04337697
Acronym
NSR-DEV
Enrollment
188
Registered
2020-04-08
Start date
2020-03-15
Completion date
2025-03-01
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy, Epilepsy, Hypoxic-Ischemic Encephalopathy, Intellectual Disability, Intracranial Hemorrhages, Neonatal Seizure, Stroke

Keywords

Family impact, Neurodevelopment

Brief summary

The NSR-DEV study is a longitudinal cohort study of around 280 Neonatal Seizure Registry participants that aims to evaluate childhood outcomes after acute symptomatic neonatal seizures, as well as examine risk factors for developmental disabilities and whether these are modified by parent well-being.

Detailed description

Neonatal seizures due to brain injury (acute symptomatic seizures) are associated with high risk of neurodevelopmental disability in infancy. Although prognosis in early childhood is a critical question for parents and providers, outcomes beyond infancy are largely unknown. Further, parents of infants with neonatal seizures are at risk for mental health disorders, which can undermine their ability to care for a child with medical complexity and may contribute to impaired child development. The NSR-DEV study is a longitudinal cohort study of around 280 Neonatal Seizure Registry participants enrolled at one of nine sites across the USA. Participants will be evaluated using developmental questionnaires and in-person neurodevelopmental testing. Parent well-being will be assessed at each time point.

Interventions

None listed

Sponsors

University of California, San Francisco
Lead SponsorOTHER
University of Michigan
CollaboratorOTHER
Stanford University
CollaboratorOTHER
Duke University
CollaboratorOTHER
Boston Children's Hospital
CollaboratorOTHER
Children's National Research Institute
CollaboratorOTHER
Massachusetts General Hospital
CollaboratorOTHER
Children's Hospital of Philadelphia
CollaboratorOTHER
Children's Hospital Medical Center, Cincinnati
CollaboratorOTHER
National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 8 Years
Healthy volunteers
No

Inclusion criteria

* Enrolled in NSR-II * Alive at the start of the NSR-DEV study period * Parent(s) who are English or Spanish literate (with assistance of interpreter)

Exclusion criteria

* Neonates who were found to have

Design outcomes

Primary

MeasureTime frameDescription
Full scale IQ (FSIQ) score for each child on the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition (WPPSI-IV)At age 5.5 years during in-person study visitThe WPPSI-IV is an in-person assessment administered by a psychologist or psychometrician that will be used to measure neurocognitive ability. Full Scale IQ (FSIQ) will be generated for each participant from the following subtests: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Fluid Reasoning Index (FRI), Working Memory Index (WMI), Processing Speed Index (PSI), Receptive Vocabulary and Picture Naming.

Secondary

MeasureTime frameDescription
Change in scores over time for each child on the Vineland Adaptive Behavior Scales, 3rd EditionAt enrollment study visit and annual visits when the child is age 3, 4, 5.5, 7, and 8The Vineland Adaptive Behavior Scales Parent Form measures adaptive behavior and intellectual and developmental function. Adaptive behavior is predictive of functional performance in school and is linked to both cognitive and executive function. Scores for each participant at each timepoint are generated based on parent reports in the following categories: Communication, Daily Living Skills, Socialization, Motor Skills, Adaptive Behavior Composite (ABC). We will look at the change in score over time for each participant during the study period after the Vineland-3 is administered at each timepoint.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORHannah C. Glass, MDCM, MAS

University of California, San Francisco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026